

BIOCON GROUP

H1 FY 2011 vs. H1 FY 2010
Q2 FY 2011 vs. Q2 FY 2010

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		<i>(Rs. Crores)</i>
Particulars	As at September-10	As at March-10
<u>SOURCES OF FUNDS</u>		
Share Capital	100	100
Reserves & Surplus	1,819	1,658
Total Shareholder's Funds	1,919	1,758
Minority interest	34	34
Deferred Tax Liability	48	51
Secured Loans	246	331
Unsecured Loans	181	182
Total Loan Funds	427	514
Total	2,427	2,356
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	1,294	1,241
Intangible Assets	250	173
Investments	367	431
Inventories	411	372
Sundry debtors	435	446
Cash and bank balances	109	140
Loans and advances	125	134
Total Current Assets, Loans & Advances	1,080	1,092
Less: Current liabilities and provisions	564	580
Net Current assets	516	512
Total	2,427	2,356

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT** (Rs Crores)

Particulars	Q2 FY 11	Q2 FY 10	Growth
<u>INCOME</u>			
Biopharmaceuticals	601	507	18%
Contract research	78	73	7%
Total Sales	679	580	17%
Other income	9	12	-26%
Total Income / Revenues	688	592	16%
<u>EXPENDITURE</u>			
Material & Power Costs	400	348	15%
Staff costs	71	57	24%
Research & Development	20	21	-6%
Forex Loss/ (gain)	(4)	(5)	-25%
Other Expenses	49	47	4%
Manufacturing, staff & other expenses	535	467	15%
PBDIT /EBIDTA	153	125	22%
Interest and finance charges	7	5	31%
PBDT	146	120	22%
Depreciation	39	35	12%
PBT	107	85	26%
Taxes	16	9	73%
PROFIT FOR THE PERIOD	91	76	20%
Add/(less): Minority interest / Share of Losses in Associates	(2)	(2)	9%
NET PROFIT (PAT)	89	74	20%
EPS Rs.₹	4.5	3.8	

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceuticals includes licensing income of Rs 23 crores in Q2 FY 2011 vs. Rs 11 crores in Q2 FY 2010

BIOCON LIMITED (CONSOLIDATED) UNAUDITED			
PROFIT & LOSS STATEMENT			<i>(Rs. Crores)</i>
Particulars	H1 FY 11	H1 FY 10	Growth
<u>INCOME</u>			
Biopharmaceuticals	1,191	939	27%
Contract research	150	137	10%
Total Sales	1,341	1,076	25%
Other income	18	22	-16%
Total Income / Revenues	1,360	1,098	24%
<u>EXPENDITURE</u>			
Material & Power Costs	807	637	27%
Staff costs	140	110	27%
Research & Development	41	41	0%
Forex Loss/ (gain)	(2)	(8)	-79%
Other Expenses	79	82	-3%
Manufacturing, staff & other expenses	1,066	862	24%
PBDIT /EBIDTA	293	236	24%
Interest and finance charges	14	11	23%
PBDT	280	225	24%
Depreciation	77	68	13%
PBT	203	158	29%
Taxes	32	23	39%
PROFIT FOR THE PERIOD	171	135	27%
Add/(less): Minority interest / Share of Losses in Associate	(5)	(3)	77%
NET PROFIT (PAT)	166	132	26%
EPS Rs.	8.5	6.8	
<i>Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers</i>			
<i>Biopharmaceuticals includes licensing income of Rs 44 crores in H1 FY 2011 vs. Rs 13 crores in H1 FY 2010.</i>			